Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.4.3.13: protein-lysine 6-oxidase

This is an abbreviated version!
For detailed information about protein-lysine 6-oxidase, go to the full flat file.

Word Map on EC 1.4.3.13

Reaction

[protein]-L-lysine
+
O2
 +
H2O
=
[protein]-(S)-2-amino-6-oxohexanoate
 +
NH3
 +
H2O2

Synonyms

elastin synthetase, LO, LOR2, LOX, LOX-like 2, LOX-like 3, LOX-like protein, LOX-PP, LOXL, LOXL-2, LOXL1, LOXL1 protein, Loxl2, LOXL2a, Loxl3, LOXL3-sv1, LOXL3a, LOXL3b, LOXL4, LOXL5a, LOXL5b, lysyl oxidase, lysyl oxidase 1, lysyl oxidase 3, lysyl oxidase homolog 2, lysyl oxidase like 4, lysyl oxidase like-1, lysyl oxidase like-1 protein, lysyl oxidase propetide, lysyl oxidase-like, lysyl oxidase-like 1, lysyl oxidase-like 2, lysyl oxidase-like 2a, lysyl oxidase-like 2b, lysyl oxidase-like 3a, lysyl oxidase-like 3b, lysyl oxidase-like 4, lysyl oxidase-like 5a, lysyl oxidase-like 5b, lysyl oxidase-like protein, lysyl oxidase-like1 protein, lysyl oxidases, More, oxidase-like protein 1, PPLO, protein-6-oxidase, protein-L-lysine:oxygen 6-oxidoreductase, protein-lysine 6-oxidase, RAS excision protein, rDmLOXL-1, WS9-14

ECTree

     1 Oxidoreductases
         1.4 Acting on the CH-NH2 group of donors
             1.4.3 With oxygen as acceptor
                1.4.3.13 protein-lysine 6-oxidase

Expression

Expression on EC 1.4.3.13 - protein-lysine 6-oxidase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
ability of torasemide to correct both lysyl oxidase overexpression and enhanced collagen cross-linking
-
enzyme expression is induced by TGFbeta treatment in smooth muscle cells
-
in MIA Paca-2 cells, silencing of apecific protein 1 (SP1) induces a reduction of LOXL2 expression
lineage-specific mutation of the type II TGFbeta receptor gene, Tgfbetar2, in both neural crest- and mesoderm-derived vascular smooth muscle precursors leads to absence of TGFbeta receptor function and reduced lysyl oxidase expression. The result is a poorly organized vascular elastic matrix in late-stage embryos, which is prone to dilation and aneurysm, due to a failure to initiate formation of the elastic matrix, rather than a failure to maintain a preexisting matrix, phenotype of Wnt1Cre/Tgfbr2 mutant embryos, overview
-
LOX and LOXL2 are induced 13 and 7.5fold, respectively, by hypoxia-inducible transcription factor-1alpha and hypoxia-inducible transcription factor-2beta
-
LOX is induced by hypoxia, loss of Pdcd4 in human nonmetastatic breast cancer cells increases the expression of LOX mRNA, and loss of Pdcd4 also augments hypoxia induction of LOX
on day 5, the signals for Lox mRNA and protein are detected in the subluminal stroma surrounding the implanting blastocyst at implantation sites while no signal is observed at interimplantation sites. From days 6 to 8 of pregnancy, the signals for Lox mRNA and protein are strongly detected in the decidual cells. The expression of Lox is under the control of estrogen via the GSK-3beta/beta-catenin/c-myc pathway
the enzyme expression is not influenced by diurnal variations, but significantly by the gender, female mice show lower enzyme mRNA expression than male ones
-
the enzyme is highly up-regulated in metastatic breast cancer cells and tissues
the enzyme is upregulated in polycystic ovarian tissue by LOX promoter binding of transcription factors, e.g. NF-kappaB and activator protein-1, induced in advanced glycation end product, AEG, signaling, overview
-
tumor suppressor Pdcd4 inhibits LOX expression, loss of Pdcd4 in human nonmetastatic breast cancer cells increases the expression of LOX mRNA